NDA 213388 · Abbvie
Oriahnn (Copackaged)
Elagolix Sodium,Estradiol,Norethindrone Acetate, Elagolix Sodium · Oral
Last checked: Nov 20, 2026Latest source record: Dec 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
May 29, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
34
15 Phase 3, 1 recruiting
FAERS reports
600
192 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: THROMBOEMBOLIC DISORDERS AND VASCULAR EVENTS Estrogen and progestin combinations, including ORIAHNN, increase the risk of thrombotic or thromboembolic disorders including pulmonary embolism, deep vein thrombosis, stroke and myocardial infarction, especially in women at increased risk for these events [see Warnings and Precautions ( 5.1 )] . ORIAHNN is contraindicated in women with current or a history of thrombotic or thromboembolic disorders and in women at increased risk for these events, including women over 35 years of age who smoke and women with uncontrolled hypertension [see Contraindications ( 4 )] . WARNING: THROMBOEMBOLIC DISORDERS AND VASCULAR EVENTS See full prescribing information for complete boxed warning. Estrogen and progestin combinations, including ORIAHNN, increase the risk of thrombotic or thromboembolic disorders, especially in women at increased risk for...
What it is approved for
From the label in effect Dec 19, 2025.
ORIAHNN is indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. Limitation of Use: Use of ORIAHNN should be limited to 24 months due to the risk of continued bone loss, which may not be reversible [see Dosage and Administration ( 2.1 ) and Warnings and Precautions ( 5.2 ) ] . ORIAHNN is a combination of elagolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, estradiol, an estrogen, and norethindrone acetate, a progestin, indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. ( 1 ) Limitation of Use: Use of ORIAHNN should be limited to 24 months due to the risk of continued bone loss, which may not be reversible. ( 1 )
Mechanism: ORIAHNN combines elagolix and estradiol/norethindrone acetate (E2/NETA), a combination of estrogen and progestin. Elagolix is a GnRH receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration of elagolix results in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased blood concentrations of the ovarian sex hormones estradiol and progesterone and reduces bleeding associated with uterine fibroids. E2 acts by binding to nuclear receptors that are...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ORIAHNN (COPACKAGED) · ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE EQ 300MG BASE,1MG,0.5MG; ELAGOLIX SODIUM EQ 300MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Elagolix" as an intervention, any sponsor and status, largest first.
- A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated PainPivotal-lookingCompleted
AbbVie (prior sponsor, Abbott)AbbVie (ABBV)
NCT01620528 · 872 participants · Start May 22, 2012 · Primary completion Nov 14, 2014
Drug: elagolix · For: Endometriosis
- A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated PainPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT01931670 · 815 participants · Start Sep 9, 2013 · Primary completion Jan 6, 2016
Drug: Elagolix · For: Endometriosis
- Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe PainPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT04333576 · 800 participants (planned) · Start Aug 10, 2020 · Primary completion Jul 2027
Drug: Elagolix; Placebo and 1 more · For: Endometriosis
Sites: Anniston, Alabama; Birmingham, Alabama; Dothan, Alabama · 179 sites in all
- A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated PainPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT03213457 · 681 participants · Start Jul 7, 2017 · Primary completion Mar 27, 2020
Drug: Estradiol/Norethindrone Acetate; Placebo for Elagolix and 2 more · For: Endometriosis
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 197 sites in all
- Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)Pivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT01817530 · 571 participants · Start Apr 8, 2013 · Primary completion Jun 2015
Drug: Elagolix; 0.5 mg estradiol / 0.1 mg norethindrone acetate and 2 more · For: Heavy Uterine Bleeding; Uterine Fibroids
- Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated PainPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT01760954 · 506 participants · Start Dec 28, 2012 · Primary completion May 2015
Drug: Elagolix · For: Endometriosis
- Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated PainPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT02143713 · 496 participants · Start May 27, 2014 · Primary completion Jun 22, 2016
Drug: Elagolix · For: Endometriosis
- Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal WomenPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT03271489 · 478 participants · Start Sep 13, 2017 · Primary completion Jun 28, 2024
Drug: Elagolix; Estradiol /norethindrone acetate (E2/NETA) · For: Heavy Menstrual Bleeding; Uterine Fibroids
Sites: Birmingham, Alabama; Dothan, Alabama; Fairhope, Alabama · 157 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- alopecia71
- heavy menstrual bleeding66
- headache56
- nausea51
- abnormal uterine bleeding34
- hot flush32
- uterine leiomyoma32
- haemorrhage29
- surgery29
- fatigue28
- intermenstrual bleeding27
- hysterectomy25
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 78 |
| 2021 | 262 |
| 2022 | 199 |
| 2023 | 44 |
| 2024 | 13 |
| 2025 | 4 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
Taylor HS, Giudice LC, Lessey BA, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Multicenter Study
- Pharmacologic Interventions for Endometriosis-Related Pain: A Systematic Review and Meta-analysis.
Kou L, Huang C, Xiao D, et al. · Obstet Gynecol 2025 · Systematic Review, Network Meta-Analysis
- Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial.
Miller CE, Kim JH, Kroll R, et al. · Am J Obstet Gynecol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy of GnRH antagonists in the treatment of uterine fibroids: a meta-analysis.
Sánchez Martín MJ, Huerga López C, Cristóbal García I, et al. · Arch Gynecol Obstet 2025 · Meta-Analysis, Review
- Cost-effectiveness of elagolix versus leuprolide acetate for treating moderate-to-severe endometriosis pain in the USA.
Wang ST, Johnson SJ, Mitchell D, et al. · J Comp Eff Res 2019 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids.
Schlaff WD, Ackerman RT, Al-Hendy A, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.